|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90 CHF | +0.99% |
|
+6.48% | +6.04% |
| Apr. 24 | BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating | MT |
| Apr. 24 | Novartis Says New Malaria Drug Formulation Safe and Effective for Babies | MT |
Drugmaker Novartis on Tuesday announced new sustainability targets, including boosting access to its medicines and global outreach as well as aiming to make its supply chain carbon neutral by 2030.
By boosting two initiatives to expand access to innovative medicines in low- and middle-income countries and to increase patient reach of programmes tackling leprosy, malaria, Chagas disease and sickle cell disease, it said it hoped to reach over 23 million patients by 2025.
(Reporting by Brenna Hughes Neghaiwi, editing by John Revill)
| 1st Jan change | Capi. | |
|---|---|---|
| +6.04% | 199B | |
| +24.17% | 562B | |
| -6.48% | 358B | |
| +19.13% | 322B | |
| +7.55% | 297B | |
| +13.45% | 219B | |
| -10.51% | 196B | |
| -11.41% | 149B | |
| -6.89% | 146B | |
| +2.07% | 117B |
NOVARTIS AG 
